中文摘要：

目的：探讨去整合素-金属蛋白酶10（ADAM10）在结直肠癌患者血清中的表达水平与结直肠癌发生、转移的关系及临床意义。方法采用酶联免疫吸附法（ELISA）检测158例结直肠癌患者、98例结直肠息肉患者及110例正常对照组中血清ADAM10、糖类抗原19-9（CA19-9）和癌胚抗原（CEA）浓度。结果结直肠癌组血清ADAM10水平显著高于结直肠息肉组和对照组（P〈0.001），肿瘤Dukes分期增加，结直肠癌组血清ADAM10水平进行性升高。结直肠癌患者血清ADAM10表达水平与性别、年龄、组织类型无关（P〉0.05），与分化程度、肿瘤的浸润深度、有无淋巴结转移及远处转移密切相关（P〈0.01）。ADAM10联合CEA、CA19-9检测，可以显著提高肿瘤诊断的准确性。结论 ADAM10在结直肠癌的诊断中有临床应用价值，有潜力成为新的肿瘤标志物。

英文摘要：

Objective To investigate the relationship between the expression lever of ADAM10 in serum of patients with occurrence and metastasis of colorectal carcinoma,and analyse its clinical significance. Methods Serum samples from 158 patients with colorectal cancer,98 patients with colorctal polyps and 110 healthy human were detected by double antibody sandwich ELISA method. At the same time,to determine the serum CA19-9,CEA evels in specimens. Results ADAM10 level in colorectal cancer patients was significantly higher than that patients with colorctal polyps and normal control.（P〈0.001）.Following with the increased Dukes stage,the serum ADAM10 level was increased. Serum ADAM10 level in the colorectal carcinoma was correlated with the differentiation,infiltration extent,lymphoid node diversion,distant metastasize（P〈0.01）,and it was no relationship with the sex,age,structure type（P〉0.05）. ADAM10 combinations of CEA and CA19-9 can increased the positive diagnosis rate of tumor. Conclusion ADAM10 has a certain clinical value in diagnosis of colorectal cancer,has the potential to become a nover tumor marker.